Clinical Trials Logo

Hemophilia A clinical trials

View clinical trials related to Hemophilia A.

Filter by:

NCT ID: NCT00166309 Completed - Clinical trials for Severe Hemophilia A With an Inhibitor

The FEIBA NovoSeven Comparative Study

Start date: July 2000
Phase: N/A
Study type: Interventional

FENOC is a prospective, open-label, randomized, cross-over, multi-center study to investigate and compare the hemostatic effect and cost-efficacy of two different by-passing agents in the treatment of joint hemorrhages in subjects with severe hemophilia A and inhibitors. The study is designed as a clinical equivalency trial.

NCT ID: NCT00162019 Completed - Hemophilia A Clinical Trials

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

Start date: March 31, 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether IMMUNATE S/D is effective and safe in the treatment of hemophilia A patients. The study consists of 3 parts: Part 1 is a pharmacokinetic comparison of IMMUNATE S/D and its predecessor IMMUNATE. Part 2 is an evaluation of efficacy and safety of IMMUNATE S/D. Part 3 is a pharmacokinetic study of IMMUNATE S/D.

NCT ID: NCT00157157 Completed - Hemophilia A Clinical Trials

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Start date: April 1, 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII (FVIII) before.

NCT ID: NCT00157105 Completed - Hemophilia A Clinical Trials

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Start date: February 12, 2001
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.

NCT ID: NCT00157053 Completed - Hemophilia A Clinical Trials

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Start date: November 22, 2001
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A subjects. The study consists of 2 parts: Part 1 is a pharmacokinetic and safety study, and Part 2 is an evaluation of efficacy and safety. The study is open to patients who completed Baxter Study 069901.

NCT ID: NCT00157040 Completed - Hemophilia A Clinical Trials

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Start date: June 7, 2002
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of children with hemophilia A. The study consists of 2 parts. Part 1 of the study is a pharmacokinetic evaluation, and Part 2 is an evaluation of efficacy and safety.

NCT ID: NCT00141843 Completed - Hemophilia A Clinical Trials

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Start date: July 2005
Phase: Phase 3
Study type: Interventional

The study will consist of two parts: a safety and efficacy period in which all subjects will participate and a pharmacokinetic analysis period, in which 30 eligible subjects will participate to compare ReFacto AF and Advate bioequivalency and safety and efficacy of ReFacto AF in patients with Hemophilia A.

NCT ID: NCT00139828 Completed - Hemophilia B Clinical Trials

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Start date: May 2003
Phase: Phase 4
Study type: Interventional

In this postmarketing study, the safety of Nonafact® (human coagulation factor IX) is evaluated in previous treated and untreated patients with severe, moderate or mild haemophilia B.

NCT ID: NCT00108797 Completed - Clinical trials for Congenital Bleeding Disorder

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Start date: September 2001
Phase: Phase 4
Study type: Interventional

This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.

NCT ID: NCT00108758 Completed - Clinical trials for Congenital Bleeding Disorder

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Start date: March 2004
Phase: Phase 2
Study type: Interventional

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.